- Home
- FFA vs CYRX Comparison
FFA vs CYRX Comparison
Compare FFA & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FFA | CYRX |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | United States |
| Employees | N/A | 1100 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 428.9M | 421.6M |
| IPO Year | 2004 | 2008 |
Fundamental Metrics
Financial Performance| Metric | FFA | CYRX |
|---|---|---|
| Price | $21.47 | $8.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $12.94 |
| AVG Volume (30 Days) | 27.0K | ★ 341.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 156.22 |
| EPS | N/A | ★ 1.40 |
| Revenue | N/A | ★ $176,177,000.00 |
| Revenue This Year | N/A | $9.71 |
| Revenue Next Year | N/A | $9.56 |
| P/E Ratio | ★ N/A | $4.99 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.00 | $4.63 |
| 52 Week High | $22.31 | $11.45 |
Technical Indicators
Market Signals| Indicator | FFA | CYRX |
|---|---|---|
| Relative Strength Index (RSI) | 38.24 | 37.26 |
| Support Level | $21.36 | $6.57 |
| Resistance Level | $21.89 | $8.45 |
| Average True Range (ATR) | 0.25 | 0.51 |
| MACD | -0.05 | 0.04 |
| Stochastic Oscillator | 7.59 | 25.71 |
Price Performance
Historical ComparisonAbout FFA First Trust Enhanced Equity Income Fund
First Trust Enhanced Equity Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide high level of current income and gains and, to a lesser extent, capital appreciation. The Fund pursues its investment objective by investing in a diversified portfolio of equity securities.
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.